News & Updates

Show Multimedia Only
Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer

Enzalutamide plus leuprolide delays metastasis, progression in prostate cancer

06 May 2026 byStephen Padilla

Prostate cancer patients treated with enzalutamide plus leuprolide have a higher probability of remaining free of distant metastasis, castration resistance, symptomatic progression, and first symptomatic skeletal event (SSE) at 5 years than those treated with leuprolide alone, as shown by the results of the EMBARK study.

06 May 2026
Optimizing treatment strategies and quality of life in patients with mHSPC

Optimizing treatment strategies and quality of life in patients with mHSPC

05 May 2026 byProf. Axel Merseburger, Department of Urology, University of Lübeck, Germany; Ms. Helen Chan, Principal Pharmacist, Chinese University of Hong Kong Medical Centre, Hong Kong

Management of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed from androgen deprivation therapy (ADT) alone to the addition of chemotherapy and androgen receptor pathway inhibitors (ARPIs) to create more efficacious treatment regimens. At an industry-sponsored meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the Department of Urology, University of Lübeck in Germany, and Ms Helen Chan, Principal Pharmacist of the Chinese University of Hong Kong Medical Centre in Hong Kong, explored how ARPI-associated advances can further optimize outcomes, not only by improving survival, but also by maintaining health-related quality of life (HRQoL) and minimizing adverse events (AEs) and critical drug–drug interactions (DDIs).

05 May 2026
Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

Scalp cooling reduces chemo-induced alopecia in gynaecological cancers

04 May 2026 byKanas Chan

Scalp cooling (or scalp hypothermia) reduces chemotherapy-induced alopecia, alleviates psychological distress, and improves quality of life (QoL) in patients with primary gynaecologic cancers receiving carboplatin plus paclitaxel, the single-centre, randomized controlled CHARM trial has shown. 

04 May 2026